ignore
=================================
CancerCat:Brain
DrugName:Autologous Tumor Lysate-Pulsed Dendritic Cell
VacTypeDesc:Dendritic Cell Vaccine
VacTypeExplain:A vaccine made of antigens and dendritic antigen-presenting cells (APCs).
VacTypeLinks:http://www.cancer.gov/Templates/db_alpha.aspx?CdrID=44949
VacTypeTrialsDesc:Dendritic Cell Therapy for Cancer
VacTypeTrials:http://www.dendritic.info/currentUsTrials.html
CompanyName:
Hosp - Jonsson Comprehensive Cancer Center
TrialName:
Vaccine Therapy in Treating Patients With Malignant Glioma
Trial Number:NCT00068510
Phase:1
Enroll:18
StartDate:06/01/2003
EndDate:
Doctor:Linda M. Liau
TrialLink:http://clinicaltrials.gov/ct/show/NCT00068510?order=2
AboutTheDrug:http://clincancerres.aacrjournals.org/cgi/content/full/11/15/5515
VacTrialID:01/01/1900
DrugPatentLink:
PriorTrialLink:
PriorTrialLink1:
PartnerID:
PartnerLink:
Commentary:
=================================
CancerCat:Brain
DrugName:Autologous Tumor Lysate-Pulsed Dendritic Cell
VacTypeDesc:Dendritic Cell Vaccine
VacTypeExplain:A vaccine made of antigens and dendritic antigen-presenting cells (APCs).
VacTypeLinks:http://www.cancer.gov/Templates/db_alpha.aspx?CdrID=44949
VacTypeTrialsDesc:Dendritic Cell Therapy for Cancer
VacTypeTrials:http://www.dendritic.info/currentUsTrials.html
CompanyName:
Hosp - Jonsson Comprehensive Cancer Center
TrialName:
Phase I Dose Escalation Study of Autologous Tumor Lysate-Pulsed Dendritic Cell I
mmunotherapy for Malignant Gliomas in Pediatric Patients
Trial Number:NCT00107185
Phase:1
Enroll:18
StartDate:04/05/2005
EndDate:04/05/2007
Doctor:Joseph L. Lasky, MD
TrialLink:http://clinicaltrials.gov/ct/show/NCT00107185?order=1
AboutTheDrug:http://www.tumorsection.org/professional/taskforce.htm
VacTrialID:01/02/1900
DrugPatentLink:
PriorTrialLink:
PriorTrialLink1:
PartnerID:
PartnerLink:
Commentary:http://www.tbts.org/itemDetail.asp?categoryID=301&itemID=17152
=================================
CancerCat:Brain
DrugName:DCVAX-Brian
VacTypeDesc:Dendritic Cell Vaccine
VacTypeExplain:A vaccine made of antigens and dendritic antigen-presenting cells (APCs).
VacTypeLinks:http://www.cancer.gov/Templates/db_alpha.aspx?CdrID=44949
VacTypeTrialsDesc:Dendritic Cell Therapy for Cancer
VacTypeTrials:http://www.dendritic.info/currentUsTrials.html
CompanyName:
Northwest Biotherapeutics Inc
TrialName:
Study of a Drug [DCVax®-Brain] to Treat Newly Diagnosed GBM Brain Cancer
Trial Number:NCT00045968
Phase:2
Enroll:141
StartDate:12/01/2006
EndDate:
Doctor:Linda Liau, MD, PhD
TrialLink:http://clinicaltrials.gov/ct/show/NCT00045968?order=1
AboutTheDrug:http://www.nwbio.com/dcvax_brain.php
VacTrialID:12/31/1899
DrugPatentLink:
PriorTrialLink:
PriorTrialLink1:
PartnerID:
PartnerLink:
Commentary:
=================================
CancerCat:Brain
DrugName:Oncophage
VacTypeDesc:Heat Shock Protein
VacTypeExplain:They act like ‘chaperones,’ making sure that the cell’s proteins are in the right shape
VacTypeLinks:http://www.antigenics.com/products/cancer/oncophage/
VacTypeTrialsDesc:GP96 Heat Shock Protein-Peptide Complex Vaccine
VacTypeTrials:http://clinicaltrials.gov/ct/show/NCT00293423?order=1
CompanyName:
Antigenics
TrialName:
GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurr
ent or Progressive Glioma
Trial Number:NCT00293423
Phase:1
Enroll:50
StartDate:11/21/2005
EndDate:
Doctor:Andrew T. Parsa, MD, PhD
TrialLink:http://www.clinicaltrials.gov/ct/show/NCT00293423?order=1
AboutTheDrug:http://www.antigenics.com/products/cancer/oncophage/
VacTrialID:01/20/1900
DrugPatentLink:
PriorTrialLink:http://pub.ucsf.edu/newsservices/releases/200704171/
PriorTrialLink1:http://www.caring4cancer.com/go/kidney/news?NewsItemId=20070416elin011.xml
PartnerID:
PartnerLink:
Commentary:http://www.abc.net.au/rn/healthreport/stories/2007/1867372.htm
=================================
CancerCat:Brain
DrugName:Novo-TTF device
VacTypeDesc:MicroWave
VacTypeExplain:Functions by producing alternating electric fields (i.e. TTFields) that are thought to disrupt cancer replication
VacTypeLinks:http://medgadget.com/archives/2007/03/novottf100a_for.html
VacTypeTrialsDesc:European Pilot Trial for Recurrent GBM Patients
VacTypeTrials:http://www.novocuretrial.com/clinical.html
CompanyName:
NovoCure Ltd
TrialName:
Effect of NovoTTF-100A in Recurrent GBM
Trial Number:NCT00379470
Phase:3
Enroll:236
StartDate:09/01/2006
EndDate:11/01/2008
Doctor:Phillip Gutin, MD
TrialLink:http://www.clinicaltrials.gov/ct/show/NCT00379470?order=1
AboutTheDrug:http://novocuretrial.com/
VacTrialID:01/23/1900
DrugPatentLink:
PriorTrialLink:http://www.touchbriefings.com/cdps/cditem.cfm?&cid=5&nid=2731
PriorTrialLink1:http://www.microwavenews.com/WeakkHz.html
PartnerID:
PartnerLink:
Commentary:http://www.pnas.org/cgi/content/abstract/104/24/10152
=================================
CancerCat:Brain
DrugName:Cotara
VacTypeDesc:Non-Vaccine - Cotara - TNT (tumor necrosis therpy)
VacTypeExplain:Links radioactive isotope to targeted monoclonal antibody
VacTypeLinks:http://www.peregrineinc.com/content.php?mi=NTY=
VacTypeTrialsDesc:Patient Enrollment In New Cotara(R) Brain Cancer Trial
VacTypeTrials:http://www.medicalnewstoday.com/articles/75228.php
CompanyName:
Peregrine Pharmaceuticals
TrialName:
Brain Cancer - Glioblastoma
Trial Number:Cotara - India
Phase:2
Enroll:40
StartDate:10/13/2006
EndDate:
Doctor:None Given
TrialLink:http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/06-25-2007/0004614602&EDATE=
AboutTheDrug:http://www.rxpgnews.com/brain-cancer/Regulatory_Approval_for_New_Cotara_R_Brain_Cancer__5063_5063.shtml
VacTrialID:01/09/1900
DrugPatentLink:
PriorTrialLink:http://www.nabtt.org/protocols/Cotara.htm
PriorTrialLink1:
PartnerID:
PartnerLink:
Commentary:http://www.medicalnewstoday.com/articles/75228.php
=================================
CancerCat:Brain
DrugName:NV1020 - Oncolytic Virus
VacTypeDesc:Oncolytic Virus
VacTypeExplain:Treatment using a virus that has been changed in the laboratory to find and destroy cancer cells without harming healthy cells. It is a type of targeted therapy.
VacTypeLinks:http://www.cancer.gov/Templates/db_alpha.aspx?CdrID=457964
VacTypeTrialsDesc:MediGene AG (DX:MDG) Release: Dose-Finding Trial Of Oncolytic Virus NV1020
VacTypeTrials:http://www.biospace.com/news_story.aspx?NewsEntityId=30358
CompanyName:
MediGene AG
TrialName:
Brain Cancer - Glioblastoma
Trial Number:NV1020-Glioblastoma - Not Started
Phase:0
Enroll:0
StartDate:
EndDate:
Doctor:
TrialLink:http://www.labtechnologist.com/news/ng.asp?n=78088-medigene-herpes-cancer-virus-tumours
AboutTheDrug:http://www.medigene.de/englisch/ProjektHSV.php
VacTrialID:01/07/1900
DrugPatentLink:
PriorTrialLink:
PriorTrialLink1:
PartnerID:
PartnerLink:
Commentary:http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowPDF&ProduktNr=230554&ArtikelNr=84480&filename=.pdf
=================================
CancerCat:Brain
DrugName:CDX-110
VacTypeDesc:Peptide Vaccine
VacTypeExplain:Vaccine in which antigens are produced from synthetic peptides and transported through the bloodstream by an adjuvant, in order to stimulate an immune response
VacTypeLinks:http://www.melanomacenter.org/glossary/p.html
VacTypeTrialsDesc:Peptide Vaccine Given with a Toll-Like Receptor Agonist
VacTypeTrials:http://cancerres.aacrjournals.org/cgi/content/abstract/67/3/1326
CompanyName:
Celldex Therapeutics
TrialName:
Phase II/III Study of CDX-110 in Patients With GBM (ACT III)
Trial Number:NCT00458601
Phase:3
Enroll:375
StartDate:04/01/2007
EndDate:12/01/2009
Doctor:Call Company
TrialLink:http://www.clinicaltrials.gov/ct/show/NCT00458601?order=1
AboutTheDrug:http://www.celldextherapeutics.com/wt/page/cdx_110
VacTrialID:01/21/1900
DrugPatentLink:http://www.freshpatents.com/Egfrviii-specific-monoclonal-antibody-and-egfrviii-ribozymes-and-use-to-detect-treat-or-prevent-egfrviii-associated-cancer-dt20051006ptan20050222059.php
PriorTrialLink:http://www.biospace.com/news_story.aspx?NewsEntityId=58603
PriorTrialLink1:http://www.genengnews.com/news/bnitem.aspx?name=18403748&taxid=29
PartnerID:
PartnerLink:
Commentary:http://sanjose.bizjournals.com/sanjose/stories/2007/04/09/story4.html
=================================
CancerCat:Brain
DrugName:HER-2/Neu Pulsed DC1 Vaccine
VacTypeDesc:Peptide Vaccine
VacTypeExplain:Vaccine in which antigens are produced from synthetic peptides and transported through the bloodstream by an adjuvant, in order to stimulate an immune response
VacTypeLinks:http://www.melanomacenter.org/glossary/p.html
VacTypeTrialsDesc:Peptide Vaccine Given with a Toll-Like Receptor Agonist
VacTypeTrials:http://cancerres.aacrjournals.org/cgi/content/abstract/67/3/1326
CompanyName:
Hosp - University of Pennsylvania - Dr. Czerniecki
TrialName:
Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Ductal Carci
noma In Situ of the Breast
Trial Number:NCT00107211
Phase:1
Enroll:30
StartDate:04/05/2005
EndDate:
Doctor:Brian J. Czerniecki
TrialLink:http://clinicaltrials.gov/ct/show/NCT00107211?order=3
AboutTheDrug:http://www.cancerportfolio.org/abstract.jsp?SID=157722&ProjectID=148448
VacTrialID:01/03/1900
DrugPatentLink:
PriorTrialLink:http://www.biologynews.net/archives/2006/11/13/novel_vaccine_shows_promise_against_earlystage_breast_cancer.html
PriorTrialLink1:http://www.oncolink.org/types/article.cfm?c=3&s=5&ss=36&id=9500
PartnerID:
PartnerLink:
Commentary:
=================================
CancerCat:Breast Cancer
DrugName:TroVax
VacTypeDesc:Antigen Vaccine
VacTypeExplain:A vaccine made of cancer cells, parts of cancer cells, or pure tumor antigens
VacTypeLinks:http://www.cancer.gov/Templates/db_alpha.aspx?CdrID=44927
VacTypeTrialsDesc:Treating Patients With Nonmetastatic Prostate Cancer
VacTypeTrials:http://clinicaltrials.gov/ct/show/NCT00450463?order=1
CompanyName:
Oxford BioMedica
TrialName:
Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Breast Cancer i
n Remission
Trial Number:NCT00227474
Phase:2
Enroll:120
StartDate:09/26/2005
EndDate:09/01/2007
Doctor:Lupe G. Salazar, MD
TrialLink:http://www.clinicaltrials.gov/ct/show/NCT00227474?order=3
AboutTheDrug:http://www.oxfordbiomedica.co.uk/trovax.htm
VacTrialID:01/17/1900
DrugPatentLink:
PriorTrialLink:http://clincancerres.aacrjournals.org/cgi/content/abstract/11/4/1512
PriorTrialLink1:
PartnerID:SNY
PartnerLink:
Commentary:http://en.sanofi-aventis.com/press/ppc_16688.asp
=================================
CancerCat:Colorectal Cancer
DrugName:NV1020 - Oncolytic Virus
VacTypeDesc:Oncolytic Virus
VacTypeExplain:Treatment using a virus that has been changed in the laboratory to find and destroy cancer cells without harming healthy cells. It is a type of targeted therapy.
VacTypeLinks:http://www.cancer.gov/Templates/db_alpha.aspx?CdrID=457964
VacTypeTrialsDesc:MediGene AG (DX:MDG) Release: Dose-Finding Trial Of Oncolytic Virus NV1020
VacTypeTrials:http://www.biospace.com/news_story.aspx?NewsEntityId=30358
CompanyName:
MediGene AG
TrialName:
Safety and Efficacy of a Genetically Engineered Herpes Simplex Virus NV1020 to T
reat Colorectal Cancer Metastatic to Liver
Trial Number:NCT00149396
NCT00149396
Phase:2
Enroll:27
StartDate:07/01/2004
EndDate:
Doctor:Hoda Tawfik, PhD
TrialLink:http://clinicaltrials.gov/ct/show/NCT00149396?order=1
AboutTheDrug:http://www.medigene.com/englisch/ProjektHSV.php
VacTrialID:01/06/1900
DrugPatentLink:
PriorTrialLink:http://www.biospace.com/news_story.aspx?NewsEntityId=30358
PriorTrialLink1:http://www.webwire.com/ViewPressRel.asp?aId=20352
PartnerID:
PartnerLink:
Commentary:
=================================
CancerCat:Head and Neck
DrugName:MAGE-A3
VacTypeDesc:Antigen Vaccine
VacTypeExplain:A vaccine made of cancer cells, parts of cancer cells, or pure tumor antigens
VacTypeLinks:http://www.cancer.gov/Templates/db_alpha.aspx?CdrID=44927
VacTypeTrialsDesc:Treating Patients With Nonmetastatic Prostate Cancer
VacTypeTrials:http://clinicaltrials.gov/ct/show/NCT00450463?order=1
CompanyName:
GlaxoSmithKline
TrialName:
MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck
Trial Number:NCT00257738
Phase:1
Enroll:90
StartDate:11/01/2005
EndDate:11/01/2006
Doctor:Scott E Strome, MD
TrialLink:http://www.clinicaltrials.gov/ct/show/NCT00257738?order=1
AboutTheDrug:http://www.gsk-us.com/ControllerServlet?appId=4&pageId=402&newsid=910
VacTrialID:01/18/1900
DrugPatentLink:http://www.freepatentsonline.com/20060222656.html
PriorTrialLink:http://www.oralcancerfoundation.org/news/story.asp?newsId=1460
PriorTrialLink1:
PartnerID:
PartnerLink:
Commentary:http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=478746
=================================
CancerCat:Lung Cancer
DrugName:MAGE-A3
VacTypeDesc:Antigen Vaccine
VacTypeExplain:A vaccine made of cancer cells, parts of cancer cells, or pure tumor antigens
VacTypeLinks:http://www.cancer.gov/Templates/db_alpha.aspx?CdrID=44927
VacTypeTrialsDesc:Treating Patients With Nonmetastatic Prostate Cancer
VacTypeTrials:http://clinicaltrials.gov/ct/show/NCT00450463?order=1
CompanyName:
GlaxoSmithKline
TrialName:
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Pat
ients With Non-Small Cell Lung Cancer
Trial Number:NCT00480025
Phase:3
Enroll:2270
StartDate:06/01/2007
EndDate:
Doctor:Clinical Trial, Study Director, GlaxoSmithKline
TrialLink:http://www.clinicaltrials.gov/ct/show/NCT00480025?order=3
AboutTheDrug:http://www.medicalnewstoday.com/articles/73327.php
VacTrialID:01/14/1900
DrugPatentLink:
PriorTrialLink:http://www.gsk.com/ControllerServlet?appId=4&pageId=402&newsid=844
PriorTrialLink1:
PartnerID:
PartnerLink:http://www.antigenics.com/news/2007/0605.phtml
Commentary:http://www.cancerindex.org/geneweb/MAGEA3.htm
=================================
CancerCat:Lung Cancer
DrugName:Stimuvax
VacTypeDesc:Tumor Cell Vaccine - Autologous
VacTypeExplain:An autologous tumor cell is a cancer cell from an individual's own tumor
VacTypeLinks:http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=43554
VacTypeTrialsDesc:Vaccination With Autologous Breast Cancer Cells Engineered
VacTypeTrials:http://clinicaltrials.gov/ct/show/NCT00317603;jsessionid=D68FD042CB9B25DDFDFD6E988039FDE8?order=1
CompanyName:
Merck KGaA
TrialName:
Cancer Vaccine Study for Unresectable Stage III Non-Small Cell Lung Cancer
Trial Number:NCT00409188
Phase:3
Enroll:1322
StartDate:12/01/2006
EndDate:12/01/2011
Doctor:Frances Shepherd, MD, FRCPC, Principal Investigator
TrialLink:http://www.clinicaltrials.gov/ct/show/NCT00409188?order=1
AboutTheDrug:http://www.biomira.com/professionals/biomiraVaccines/BLP25/
VacTrialID:01/13/1900
DrugPatentLink:
PriorTrialLink:http://www.biomira.com/pipeline/stimuvax/
PriorTrialLink1:http://www.psa-rising.com/wiredbird/biomira_stimuvax06.html
PartnerID:BIOM
PartnerLink:http://www.healthcare-digital.co.uk/Biomira-announces-new-COO_1116.aspx
Commentary:http://www.biomira.com/pipeline/stimuvax/
=================================
CancerCat:Lung Cancer
DrugName:VaxImmune
VacTypeDesc:Vaccine Adjuvant - VaxImmune
VacTypeExplain:VaxImmune is a proprietary TLR9 agonist
VacTypeLinks:http://money.aol.com/news/articles/_a/coley-pharmaceutical-groups-vaccine/n20070605095209990013
VacTypeTrialsDesc:
VacTypeTrials:
CompanyName:
Coley Pharmaceutical
TrialName:
GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Pat
ients With Non-Small Cell Lung Cancer
Trial Number:NCT00480025
Phase:3
Enroll:2270
StartDate:06/01/2007
EndDate:
Doctor:Clinical Trial, Study Director, GlaxoSmithKline
TrialLink:http://www.clinicaltrials.gov/ct/show/NCT00480025?order=3
AboutTheDrug:http://www.coleypharma.com/product-pipeline/vaccine-adjuvant.cfm
VacTrialID:01/19/1900
DrugPatentLink:
PriorTrialLink:
PriorTrialLink1:
PartnerID:
PartnerLink:http://money.aol.com/news/articles/_a/coley-pharmaceutical-groups-vaccine/n20070605095209990013
Commentary:http://www.medicalnewstoday.com/articles/58555.php
=================================
CancerCat:Melanoma
DrugName:UVIDEM (IDD-3)
VacTypeDesc:Dendritic Cell Vaccine
VacTypeExplain:A vaccine made of antigens and dendritic antigen-presenting cells (APCs).
VacTypeLinks:http://www.cancer.gov/Templates/db_alpha.aspx?CdrID=44949
VacTypeTrialsDesc:Dendritic Cell Therapy for Cancer
VacTypeTrials:http://www.dendritic.info/currentUsTrials.html
CompanyName:
IDM Pharma, Inc.
TrialName:
Vaccine Therapy in Treating Patients With Unresected Stage III or Stage IV Melan
oma
Trial Number:NCT00107159
Phase:2
Enroll:30
StartDate:01/01/2005
EndDate:
Doctor:Antoni Ribas, MD
TrialLink:http://clinicaltrials.gov/ct/show/NCT00107159?order=1
AboutTheDrug:http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=427285
VacTrialID:01/04/1900
DrugPatentLink:
PriorTrialLink:http://ir.idm-biotech.com/phoenix.zhtml?c=193146&p=irol-newsArticle&ID=1011304&highlight=
PriorTrialLink1:http://meeting.jco.org/cgi/content/abstract/25/18_suppl/3004
PartnerID:SNY
PartnerLink:http://en.sanofi-aventis.com/rd/portfolio/p_rd_portfolio_oncology.asp
Commentary:http://www.idm-biotech.com/index.jsp;jsessionid=5316EB11FCB1640B502D34F8BD9BCA3B?workspace=197&_seid=5316EB11FCB1640B502D34F8BD9BCA3B
=================================
CancerCat:Ovarian Cancer
DrugName:Abagovomab
VacTypeDesc:Anti-idiotype vaccine
VacTypeExplain:A vaccine made of antibodies that see other antibodies as the antigen and bind to it
VacTypeLinks:http://www.cancer.gov/Templates/db_alpha.aspx?searchTxt=Anti-Idiotype+Vaccine&sgroup=Starts+with&lang=&btnGo.x=19&btnGo.y=9
VacTypeTrialsDesc:Phase I clinical trial of a human idiotypic p53
VacTypeTrials:http://annonc.oxfordjournals.org/cgi/content/full/15/2/324
CompanyName:
Menarini Group
TrialName:
Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat
Ovarian Cancer Patients (MIMOSA)
Trial Number:NCT00418574
Phase:3
Enroll:870
StartDate:12/01/2006
EndDate:12/01/2015
Doctor:Jacobus Pfisterer, MD
TrialLink:http://www.clinicaltrials.gov/ct/show/NCT00418574?order=1
AboutTheDrug:http://www.menarini.com/english/ricerca_sviluppo/abagovomab.htm
VacTrialID:01/12/1900
DrugPatentLink:
PriorTrialLink:http://clincancerres.aacrjournals.org/cgi/content/abstract/12/18/5503
PriorTrialLink1:
PartnerID:
PartnerLink:
Commentary:http://annonc.oxfordjournals.org/cgi/content/abstract/17/10/1568
=================================
CancerCat:Pancreatic
DrugName:GV1001
VacTypeDesc:Peptide Vaccine
VacTypeExplain:Vaccine in which antigens are produced from synthetic peptides and transported through the bloodstream by an adjuvant, in order to stimulate an immune response
VacTypeLinks:http://www.melanomacenter.org/glossary/p.html
VacTypeTrialsDesc:Peptide Vaccine Given with a Toll-Like Receptor Agonist
VacTypeTrials:http://cancerres.aacrjournals.org/cgi/content/abstract/67/3/1326
CompanyName:
Pharmexa A/S
TrialName:
GV1001 and Gemcitabine in Sequential Combination to Gemcitabine Monotherapy in P
ancreatic Cancer.
`
Trial Number:NCT00358566
Phase:3
Enroll:520
StartDate:06/01/2006
EndDate:10/01/2008
Doctor:None Given
TrialLink:http://clinicaltrials.gov/ct/show/NCT00358566?order=1
AboutTheDrug:http://www.pharmexa.com/site.asp?p=506
VacTrialID:01/05/1900
DrugPatentLink:
PriorTrialLink:http://meeting.jco.org/cgi/content/abstract/23/16_suppl/2580
PriorTrialLink1:http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/05-16-2005/0003630414&EDATE=
PartnerID:
PartnerLink:
Commentary:http://www.cancerhelp.org.uk/trials/trials/trial.asp?=&trialno=9724
=================================
CancerCat:Pancreatic
DrugName:GV1001
VacTypeDesc:Peptide Vaccine
VacTypeExplain:Vaccine in which antigens are produced from synthetic peptides and transported through the bloodstream by an adjuvant, in order to stimulate an immune response
VacTypeLinks:http://www.melanomacenter.org/glossary/p.html
VacTypeTrialsDesc:Peptide Vaccine Given with a Toll-Like Receptor Agonist
VacTypeTrials:http://cancerres.aacrjournals.org/cgi/content/abstract/67/3/1326
CompanyName:
Pharmexa A/S
TrialName:
Gemcitabine and Capecitabine With or Without Vaccine Therapy in Treating Patient
s With Locally Advanced or Metastatic Pancreatic Cancer
Trial Number:NCT00425360
Phase:3
Enroll:1110
StartDate:09/01/2006
EndDate:
Doctor:Gary W. Middleton
TrialLink:http://clinicaltrials.gov/ct/show/NCT00425360?order=3
AboutTheDrug:http://www.pharmexa.com/site.asp?p=506
VacTrialID:01/11/1900
DrugPatentLink:
PriorTrialLink:http://www.pharmacychoice.com/News/article.cfm?Article_ID=40300
PriorTrialLink1:
PartnerID:
PartnerLink:
Commentary:http://www.eurekalert.org/pub_releases/2007-03/uol-ltt031507.php
=================================
CancerCat:Prostate
DrugName:VPM4001
VacTypeDesc:Tumor Cell Vaccine - Allogeneic
VacTypeExplain:Vaccine composed of tumor cells isolated from the tumor of one patient, killed and processed, and administered to another patient in order to stimulate cytotoxic immune responses
VacTypeLinks:http://www.cancer.gov/Templates/drugdictionary.aspx?CdrID=350082
VacTypeTrialsDesc:Vaccine Therapy in Treating Patients With Pancreatic Cancer
VacTypeTrials:http://clinicaltrials.gov/ct/show/NCT00389610;jsessionid=C6A32B6FFBB949FE645AEBEFDDFA3F35?order=37
CompanyName:
Vakzine Projekt Management
TrialName:
Phase I/II Prostate Cancer
Trial Number:Unknown
Phase:2
Enroll:30
StartDate:
EndDate:
Doctor:
TrialLink:http://www.psa-rising.com/wiredbird/vakzinepm0607.html
AboutTheDrug:http://www.vakzine-manager.de/Allogeneic_Cancer_Va.167.0.html?&L=1#553
VacTrialID:01/22/1900
DrugPatentLink:
PriorTrialLink:http://www.allbusiness.com/services/business-services/4345807-1.html
PriorTrialLink1:
PartnerID:
PartnerLink:
Commentary:http://www.micromedex.com/pressroom/news_feeds/?story_ID=129138&category=16
=================================
CancerCat:Renal Cell Carcinoma
DrugName:TroVax
VacTypeDesc:Antigen Vaccine
VacTypeExplain:A vaccine made of cancer cells, parts of cancer cells, or pure tumor antigens
VacTypeLinks:http://www.cancer.gov/Templates/db_alpha.aspx?CdrID=44927
VacTypeTrialsDesc:Treating Patients With Nonmetastatic Prostate Cancer
VacTypeTrials:http://clinicaltrials.gov/ct/show/NCT00450463?order=1
CompanyName:
Oxford BioMedica
TrialName:
A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage
IV Renal Cell Cancer
Trial Number:NCT00083941
Phase:2
Enroll:25
StartDate:08/01/2004
EndDate:
Doctor:Howard L Kaufman, MD
TrialLink:http://www.clinicaltrials.gov/ct/show/NCT00083941?order=2
AboutTheDrug:http://www.oxfordbiomedica.co.uk/trovax.htm
VacTrialID:01/16/1900
DrugPatentLink:
PriorTrialLink:http://www.medicalnewstoday.com/articles/31823.php
PriorTrialLink1:http://www.bioportfolio.com/oct_05/07_10_2005/Oxford_Biomedica_Plc.html
PartnerID:SNY
PartnerLink:
Commentary:
=================================
CancerCat:Renal Cell Carcinoma
DrugName:TroVax
VacTypeDesc:Antigen Vaccine
VacTypeExplain:A vaccine made of cancer cells, parts of cancer cells, or pure tumor antigens
VacTypeLinks:http://www.cancer.gov/Templates/db_alpha.aspx?CdrID=44927
VacTypeTrialsDesc:Treating Patients With Nonmetastatic Prostate Cancer
VacTypeTrials:http://clinicaltrials.gov/ct/show/NCT00450463?order=1
CompanyName:
Oxford BioMedica
TrialName:
TroVax Renal Immunotherapy Survival Trial
Trial Number:NCT00397345
Phase:3
Enroll:700
StartDate:09/01/2006
EndDate:
Doctor:None Given
TrialLink:http://www.clinicaltrials.gov/ct/show/NCT00397345?order=1
AboutTheDrug:http://www.oxfordbiomedica.co.uk/trovax.htm
VacTrialID:01/15/1900
DrugPatentLink:
PriorTrialLink:http://www.medicalnewstoday.com/articles/31823.php
PriorTrialLink1:http://www.emaxhealth.com/95/12642.html
PartnerID:SNY
PartnerLink:http://www.drugresearcher.com/news/ng.asp?n=75395-sanofi-aventis-oxford-biomedica-trovax-cancer-vaccine-glaxosmithkline
Commentary:http://en.wikipedia.org/wiki/TroVax
=================================
keyword:
CRACKER |
